Rodman & Renshaw Initiates Coverage of Elicio Therapeutics (ELTX) with Buy Recommendation

Rodman & Renshaw initiated coverage of Elicio Therapeutics (NasdaqCM: ELTX) on March 10, 2026 with a Buy recommendation, and the analyst price target implies a 22.56% upside. This is a moderately positive, analyst-driven signal likely to attract short-term investor interest in ELTX but does not reflect a company operational or clinical update.

Analysis

Rodman & Renshaw initiated coverage of Elicio Therapeutics (NasdaqCM: ELTX) on March 10, 2026 with a Buy recommendation, and the analyst price target implies a 22.56% upside. This is a moderately positive, analyst-driven signal likely to attract short-term investor interest in ELTX but does not reflect a company operational or clinical update.